Answers are grounded in this paper and cite their sources.
Patients needing long-term platelet transfusion support become alloimmunized to transplantation (HL-A) antigens present in random-donor blood products, which results in refractoriness to platelets from unselected donors. Three thousand HL-A typed donors were used to evaluate the effectiveness of selecting unrelated platelet donors for alloimmunized patients by donor-recipient lymphocyte HL-A compatibility. Platelet transfusions from HL-A compatible donors resulted in increased platelet increments after transfusion. There was a positive correlation between the degree of donor-recipient HL-A compatibility and the transfusion response; the responses to platelets from A-matched donors (HL-A identical) and B-1-matched donors (HL-A compatible, one recipient antigen not present in the donor) were similar to platelet transfusions from HL-A identical siblings. ABO-incompatibility of HL-A compatible platelet donors did not affect the posttransfusion platelet increments. HL-A compatible platelet donors can be used effectively for transfusion support of alloimmunized patients.
No takes yet. Share an insight, caveat, or question.
Hans‐Peter Lohrmann (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: